Hypro Diagnostics relies on a crucial diagnostic tool known as the double marker test, an essential screening method conducted in the initial stages of pregnancy. This test aims to evaluate the likelihood of Down’s syndrome and other chromosomal anomalies in the developing fetus. By analyzing the levels of the free beta subunit of human chorionic gonadotrophin (HCG) and pregnancy-associated plasma protein-A (PAPP-A) in the blood of pregnant women, Hypro Diagnostics seeks to provide comprehensive insights. The significance of free beta HCG, a placenta-secreted hormone, is paramount in detecting Down’s syndrome. When combined with factors like maternal age and ultrasonographic assessment of nuchal translucency during the 11th to 14th weeks of pregnancy, the results contribute to a thorough evaluation. Elevated free beta HCG levels, along with PAPP-A and other considerations, empower Hypro Diagnostics to offer valuable information for predicting and identifying potential chromosomal anomalies, facilitating early detection and informed decision-making for expectant parents.
Reviews
There are no reviews yet.